表紙
市場調查報告書

特發性肺纖維化市場:各藥物類型,地區 - 全球機會分析及產業預測

Idiopathic Pulmonary Fibrosis Market by Type of Drug (Pirfenidone, Nintedanib) and Region (North America, Europe, Asia-Pacific, and LAMEA) - Global Opportunity Analysis and Industry Forecast, 2017-2023

出版商 Allied Market Research 商品編碼 563322
出版日期 內容資訊 英文 150 Pages
商品交期: 2-3個工作天內
價格
特發性肺纖維化市場:各藥物類型,地區 - 全球機會分析及產業預測 Idiopathic Pulmonary Fibrosis Market by Type of Drug (Pirfenidone, Nintedanib) and Region (North America, Europe, Asia-Pacific, and LAMEA) - Global Opportunity Analysis and Industry Forecast, 2017-2023
出版日期: 2017年09月01日內容資訊: 英文 150 Pages
簡介

本報告提供全球特發性肺纖維化市場相關調查,市場的各藥物類型,各地區趨勢,及打入市場的主要企業簡介等彙整資料。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 主要調查結果
  • 市場佔有率分析
  • 市場趨勢
    • 促進要素
    • 阻礙要素
    • 機會

第4章 各藥物類型市場

  • 概要
  • Pirfenidone
    • 市場趨勢
    • 成長因素和機會
    • 市場規模與預測
  • Nintedanib
    • 市場趨勢
    • 成長因素和機會
    • 市場規模與預測

第5章 各地區市場

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美

第6章 企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: LI 04407

Idiopathic pulmonary fibrosis is a condition in which the tissues in the lungs become thick and stiff over time. As a result of thickening of lung tissues, brain and other organs are unable receive optimum oxygen.

The global idiopathic pulmonary fibrosis market generated $1,616 million in 2016, and is projected to reach $3,569 million by 2023, registering a CAGR of 11.9% during the study period. The major factors that drive the growth of the global idiopathic pulmonary fibrosis market include rise in prevalence of fibrotic disease and increase in geriatric population. In addition, surge in demand for cost-effective drugs and introduction of advanced treatment options propel the market growth. However, unavailability of the proper treatment options of the disease restricts the market growth.

The global idiopathic pulmonary fibrosis market is segmented on the basis of type of drug and region. According to type of drug, the market is divided into pirfenidone and nintedanib. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The report provides an in-depth analysis of parent market trends, macro-economic indicators, and governing factors.
  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the market from 2016 to 2023 that helps identify the upcoming market opportunities.
  • Recent industry trends and developments and the future opportunities are also covered.
  • Extensive knowledge about the key market players and their strategies is provided.
  • Comprehensive analysis of the various factors that drive and restrain the growth of the market is provided.

Key Market Segments

By Type of Drug

  • Pirfenidone
  • Nintedanib

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • France
  • Germany
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
  • Key market players

The key players operating in this market include

  • MediciNova, Inc.
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • FibroGen, Inc.
  • Promedior, Inc.
  • Merck & Co., Inc.
  • Galapagos NV
  • Biogen
  • Bristol-Myers Squibb Company
  • Prometic Life Sciences Inc.
  • Cipla Inc.

Table of Contents

CHAPTER 1 INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. KEY BENEFITS FOR STAKEHOLDERS
  • 1.3. KEY MARKET SEGMENTS
  • 1.4. RESEARCH METHODOLOGY
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

  • 2.1. KEY FINDINGS OF THE STUDY
  • 2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

  • 3.1. MARKET DEFINITION AND SCOPE
  • 3.2. KEY FINDINGS
    • 3.2.1. Top winning strategies
    • 3.2.2. Top investment pockets
  • 3.3. MARKET SHARE ANALYSIS, 2016
  • 3.4. MARKET DYNAMICS
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities
    • 3.4.4. Impact analysis

CHAPTER 4 GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE

  • 4.1. OVERVIEW
    • 4.1.1. Market size and forecast
  • 4.2. PIRFENIDONE
    • 4.2.1. Key market trends
    • 4.2.2. Growth factors and opportunities
    • 4.2.3. Market size and forecast
  • 4.3. NINTEDANIB
    • 4.3.1. Key market trends
    • 4.3.2. Growth factors and opportunities
    • 4.3.3. Market size and forecast

CHAPTER 5 IDIOPATHIC PULMONARY FIBROSIS MARKET, BY REGION

  • 5.1. OVERVIEW
    • 5.1.1. Market size and forecast
  • 5.2. NORTH AMERICA
    • 5.2.1. Key market trends
    • 5.2.2. Key growth factors and opportunities
    • 5.2.3. Market size and forecast
    • 5.2.4. U.S.
    • 5.2.5. Canada
    • 5.2.6. Mexico
  • 5.3. EUROPE
    • 5.3.1. Key market trends
    • 5.3.2. Key growth factors and opportunities
    • 5.3.3. Market size and forecast
    • 5.3.4. Germany
    • 5.3.5. France
    • 5.3.6. UK
    • 5.3.7. Italy
    • 5.3.8. Spain
    • 5.3.9. Rest of Europe
  • 5.4. ASIA-PACFIC
    • 5.4.1. Key market trends
    • 5.4.2. Key growth factors and opportunities
    • 5.4.3. Market size and forecast
    • 5.4.4. Japan
    • 5.4.5. China
    • 5.4.6. India
    • 5.4.7. South Korea
    • 5.4.8. Rest of Asia-Pacific
  • 5.5. LAMEA
    • 5.5.1. Key market trends
    • 5.5.2. Key growth factors and opportunities
    • 5.5.3. Market size and forecast
    • 5.5.4. Brazil
    • 5.5.5. South Africa
    • 5.5.6. Saudi Arabia
    • 5.5.7. Rest of LAMEA

CHAPTER 6 COMPANY PROFILES

  • 6.1. MEDICINOVA, INC.
    • 6.1.1. Company overview
    • 6.1.2. Operating business segments
    • 6.1.3. Business performance
    • 6.1.4. Key strategic moves and developments
  • 6.2. BOEHRINGER INGELHEIM
    • 6.2.1. Company overview
    • 6.2.2. Operating business segments
    • 6.2.3. Business performance
    • 6.2.4. Key strategic moves and developments
  • 6.3. F. HOFFMANN-LA ROCHE
    • 6.3.1. Company overview
    • 6.3.2. Operating business segments
    • 6.3.3. Business performance
    • 6.3.4. Key strategic moves and developments
  • 6.4. FIBROGEN, INC.
    • 6.4.1. Company overview
    • 6.4.2. Operating business segments
    • 6.4.3. Business performance
    • 6.4.4. Key strategic moves and developments
  • 6.5. PROMEDIOR, INC.
    • 6.5.1. Company overview
    • 6.5.2. Operating business segments
    • 6.5.3. Business performance
    • 6.5.4. Key strategic moves and developments
  • 6.6. MERCK & CO., INC.
    • 6.6.1. Company overview
    • 6.6.2. Operating business segments
    • 6.6.3. Business performance
    • 6.6.4. Key strategic moves and developments
  • 6.7. GALAPAGOS NV
    • 6.7.1. Company overview
    • 6.7.2. Operating business segments
    • 6.7.3. Business performance
    • 6.7.4. Key strategic moves and developments
  • 6.8. BIOGEN
    • 6.8.1. Company overview
    • 6.8.2. Operating business segments
    • 6.8.3. Business performance
    • 6.8.4. Key strategic moves and developments
  • 6.9. BRISTOL-MYERS SQUIBB COMPANY
    • 6.9.1. Company overview
    • 6.9.2. Operating business segments
    • 6.9.3. Business performance
    • 6.9.4. Key strategic moves and developments
  • 6.10. PROMETIC LIFE SCIENCES INC.
    • 6.10.1. Company overview
    • 6.10.2. Operating business segments
    • 6.10.3. Business performance
    • 6.10.4. Key strategic moves and developments
  • 6.11. CIPLA INC.
    • 6.11.1. Company overview
    • 6.11.2. Operating business segments
    • 6.11.3. Business performance
    • 6.11.4. Key strategic moves and developments

List of Tables

  • TABLE 1. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
  • TABLE 2. PIRFENIDONE MARKET, BY REGION, 2016-2023, ($MILLION)
  • TABLE 3. PIRFENIDONE MARKET, BY COUNTRY, 2016-2023, ($MILLION)
  • TABLE 4. NINTEDANIB MARKET, BY REGION, 2016-2023, ($MILLION)
  • TABLE 5. NINTEDANIB MARKET, BY COUNTRY, 2016-2023, ($MILLION)
  • TABLE 6. IDIOPATHIC PULMONARY FIBROSIS MARKET, BY REGION, 2016-2023, ($MILLION)
  • TABLE 7. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2016-2023, ($MILLION)
  • TABLE 8. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
  • TABLE 9. U.S. IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
  • TABLE 10. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
  • TABLE 11. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
  • TABLE 12. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2016-2023, ($MILLION)
  • TABLE 13. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
  • TABLE 14. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
  • TABLE 15. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
  • TABLE 16. UK IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
  • TABLE 17. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
  • TABLE 18. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
  • TABLE 19. REST OF EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
  • TABLE 20. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2016-2023, ($MILLION)
  • TABLE 21. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
  • TABLE 22. JAPAN IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
  • TABLE 23. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
  • TABLE 24. INDIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
  • TABLE 25. SOUTH KOREA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
  • TABLE 26. REST OF ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
  • TABLE 27. LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2016-2023, ($MILLION)
  • TABLE 28. LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE, 2016-2023, ($MILLION)
  • TABLE 29. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
  • TABLE 30. SOUTH AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
  • TABLE 31. SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
  • TABLE 32. REST OF LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
  • TABLE 33. MEDICINOVA, INC.: COMPANY SNAPSHOT
  • TABLE 34. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
  • TABLE 35. ROCHE: COMPANY SNAPSHOT
  • TABLE 36. FIBROGEN: COMPANY SNAPSHOT
  • TABLE 37. PROMEDIOR: COMPANY SNAPSHOT
  • TABLE 38. MERCK: COMPANY SNAPSHOT
  • TABLE 39. GALAPAGOS: COMPANY SNAPSHOT
  • TABLE 40. BIOGEN: COMPANY SNAPSHOT
  • TABLE 41. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
  • TABLE 42. PROMETIC LIFE SCIENCES INC.: COMPANY SNAPSHOT
  • TABLE 43. CIPLA INC.: COMPANY SNAPSHOT

List of Figures

  • FIGURE 1. IDIOPATHIC PULMONARY FIBROSIS MARKET SEGMENTATION
  • FIGURE 2. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (20142016)
  • FIGURE 3. TOP WINNING STRATEGIES: NATURE AND TYPE
  • FIGURE 4. TOP WINNING STRATEGIES: NATURE AND COMPANY
  • FIGURE 5. TOP INVESTMENT POCKETS
  • FIGURE 6. MARKET SHARE ANALYSIS, 2016
  • FIGURE 7. IMPACT ANALYSIS, 2016